Aaron Michael Paplaskas, RN in Chester, NH - Registered Nurse

Aaron Michael Paplaskas, RN is a Registered Nurse - Critical Care Medicine based in Chester, New Hampshire. Aaron Michael Paplaskas is licensed to practice in New Hampshire (license number 069835-21) and his current practice location is 6 Meadow Fox Ln, Chester, New Hampshire. He can be reached at his office (for appointments etc.) via phone at (606) 303-4417.

NPI number for Aaron Michael Paplaskas is 1316584188 and his current mailing address is 6 Meadow Fox Ln, Chester, New Hampshire. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1316584188.

Contact Information

	Aaron Michael Paplaskas, RN
	6 Meadow Fox Ln, Chester, NH 03036-4186
	(606) 303-4417
	Not Available

Provider's Profile

Full Name	Aaron Michael Paplaskas
Gender	Male
Speciality	Registered Nurse - Critical Care Medicine
Location	6 Meadow Fox Ln, Chester, New Hampshire
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1316584188
Provider Enumeration Date: 11/29/2019
Last Update Date: 11/29/2019

Medical Identifiers

Medical identifiers for Aaron Michael Paplaskas such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1316584188	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
163WC0200X	Registered Nurse - Critical Care Medicine	069835-21 (New Hampshire)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Aaron Michael Paplaskas is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Aaron Michael Paplaskas, RN 6 Meadow Fox Ln, Chester, NH 03036-4186 Ph: (606) 303-4417	Aaron Michael Paplaskas, RN 6 Meadow Fox Ln, Chester, NH 03036-4186 Ph: (606) 303-4417

News Archive

Health on The Hill – October 27, 2010

Kaiser Health News staff writer Mary Agnes Carey talks with The Fiscal Times' Eric Pianin and KFF's Jackie Judd about the latest news in politics and health policy.

FDA grants IND regulatory clearance for Phase I/II clinical trial of AAT in type 1 diabetics

The U.S. Food & Drug Administration (FDA) has granted Investigational New Drug (IND) regulatory clearance to initiate a Phase I/II clinical trial evaluating Alpha-1 Antitrypsin (AAT) in type 1 diabetics, based on research by Dr. Eli Lewis of Israel's Ben-Gurion University of the Negev.

GABA disrupts working memory in neurofibromatosis type 1 patients

Imagine if your brain lost its working memory - the ability to hold and manipulate information in your mind's eye. That's the plight faced by millions of people with neurofibromatosis type 1, or NF1. The genetic condition affects one in 3,500 people and is the most common cause of learning disabilities.Now a UCLA research team has uncovered new clues about how NF1 disrupts working memory. Published in the July 12 online edition of Proceedings of the National Academy of Sciences, the findings suggest a potential drug target for correcting NF1-related learning disabilities.

Kidney transplants more frequent among NxStage home hemodialysis patients

NxStage Medical, Inc., a leading manufacturer of innovative dialysis products, today commented on findings of the Chronic Disease Research Group (CDRG) study showing that patients receiving daily, or more frequent, home hemodialysis with the NxStage System One are more likely to receive a kidney transplant when compared with conventional thrice-weekly dialysis, particularly in patients not on the transplant waitlist at initiation of daily home hemodialysis.

Aaron Michael Paplaskas, RN - Registered Nurse in Chester, NH